[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Abeer Mohamed Abdelaziz Elkholy\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":46},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":5},"100616975",false,"NCT07312604","A Pilot Study to Evaluate the Therapeutic Efficacy of Intra-Lesional Immunotherapy in Patients Aged 10-60 Years With Recalcitrant Tinea Cruris and Corporis","Evaluating the Therapeutic Efficacy of Intra-lesional Immunotherapy Against Recalcitrant Tinea Cruris & Corporis: a Pilot Study","IL-ImmuneRTC","Inclusion Criteria:\n\n* Age between 10 - 60 years.\n* Evidence of recalcitrant tinea e.g. (rapid progression \\& large areas affected of the body, affection of more than one family members especially females \\& children, rapid relapse after treatment, suspicion of resistant T. indotineae strain by history of traveling abroad \\& contact with Indians or contact with a case coming from travel \\& with contact to Indians.\n* Patients failed at least 2 courses of systemic antifungal therapy in the last 3 months.\n* Safe contraception during the study (for females in the childbearing period).\n\nExclusion Criteria:\n\n* Pregnant or lactating women, as well as women of childbearing potential not using an effective method of contraception.\n* Age \\\u003C10 years or \\> 60 years.\n* Immunocompromised patients e.g. (uncontrolled DM or HIV patients).\n* Naïve patients without previous systemic antifungal treatment.\n* Unreliable patients.","ALL","10 Years","60 Years",{"count":20,"type":21},50,"ESTIMATED","INTERVENTIONAL",[24],"NA","This pilot study will test intra-lesional immunotherapy (MMR vaccine) injections as a treatment for recalcitrant tinea cruris and corporis in patients aged 10-60 years who have not improved with standard antifungal treatments.\n\n\\*Eligibility: Participants must have recalcitrant tinea, defined as:\n\n* Rapid progression or large areas of skin affected,\n* Infection in multiple family members, especially females and children\n* Rapid relapse after prior treatment\n* Suspected resistant T. indotineae (based on travel history or contact with affected individuals from high-prevalence regions)\n* Failure of at least 2 courses of systemic antifungal therapy in the past 3 months\n\nTreatment: Patients will receive intra-lesional MMR vaccine injections into the active borders of affected lesions every 2 weeks for up to 6 weeks. If partial improvement occurs but complete clearance is not achieved, the course may be repeated for another 6 weeks. Pulse itraconazole will be given during the first 2 weeks.\n\nMonitoring: At each study visit, clinicians will assess the extent of affected skin and monitor symptoms particularly itching. Safety will be closely observed, including injection-site reactions, fever, initial flare of lesions, and any rare serious allergic reactions.\n\nGoal: To evaluate the safety and effectiveness of intra-lesional MMR immunotherapy for patients with tinea that has been difficult to treat.",[27,28],"Tinea Corporis","Tinea Cruris",[28,27,30,31,32,33],"Recalcitrant Dermatophytosis","Intra-Lesional Immunotherapy","Pilot Clinical Study","Dermatophyte Treatment","RECRUITING","2025-12-17",{"date":37,"type":38},"2025-12-31","ACTUAL",{"date":40,"type":38},"2025-12-09",{"date":42,"type":21},"2026-03-09",{"name":44,"class":45},"Abeer Mohamed Abdelaziz Elkholy","OTHER",""]